


URGENT: SAFETY ALERT

GILEAD SCIENCES, INC.

January 29, 2010

Revised: Updated Phone Number

PRODUCT	Product: Ranexa® extended-release tablets (ranolazine) NDC: 67159-112-03, 500 mg 67159-114-03, 1000 mg Package Size: Bottles of 60 tablets Lot Number: All
REASON	Ranexa packaging may not meet child-resistant packaging requirements.
ACTION	<ol style="list-style-type: none">1. Dispense Ranexa tablets into child-resistant packaging.2. Do not dispense Ranexa to patients in its original packaging (rectangular bottle). <div data-bbox="636 716 1395 1203"></div>
OTHER INFORMATION	<p>This notification is being distributed to the wholesaler and pharmacy level.</p> <p>We expect to begin shipping Ranexa in a new child-resistant packaging configuration by February 8, 2010 (500 mg) and February 15, 2010 (1000 mg). The new packaging will consist of a round bottle rather than a rectangular bottle and will be labeled with the Gilead trademark instead of the CV Therapeutics trademark. As soon as you begin receiving and distributing this new packaging (round bottle), it will no longer be necessary to repackage Ranexa.</p> <p>This action is being taken in cooperation with the Consumer Product Safety Commission. We appreciate your immediate attention and cooperation and sincerely regret any inconvenience caused by this action.</p> <p>For medical questions or further information please contact Gilead Medical Information at 901-578-9313.</p>